Pulmatrix, Inc. (PULM)
NASDAQ: PULM · Real-Time Price · USD
6.06
+0.30 (5.25%)
Dec 24, 2024, 12:57 PM EST - Market closed
Pulmatrix Revenue
Pulmatrix had revenue of $366.00K in the quarter ending September 30, 2024, a decrease of -79.12%. This brings the company's revenue in the last twelve months to $10.01M, up 47.05% year-over-year. In the year 2023, Pulmatrix had annual revenue of $7.30M with 20.21% growth.
Revenue (ttm)
$10.01M
Revenue Growth
+47.05%
P/S Ratio
2.21
Revenue / Employee
$454,773
Employees
22
Market Cap
22.14M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 7.30M | 1.23M | 20.21% |
Dec 31, 2022 | 6.07M | 902.00K | 17.45% |
Dec 31, 2021 | 5.17M | -7.47M | -59.09% |
Dec 31, 2020 | 12.63M | 4.72M | 59.72% |
Dec 31, 2019 | 7.91M | 7.76M | 5,069.93% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
HOOKIPA Pharma | 50.00M |
Equillium | 45.91M |
BioLineRx | 21.99M |
Vivos Therapeutics | 14.58M |
NeurAxis | 2.46M |
iBio, Inc. | 175.00K |
Gelteq | 95.62K |
PULM News
- 5 weeks ago - SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM and ENTO on Behalf of Shareholders - Accesswire
- 5 weeks ago - PULMATRIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pulmatrix, Inc. - PULM - Business Wire
- 6 weeks ago - Pulmatrix and Cullgen Announce Proposed Merger - PRNewsWire
- 6 weeks ago - Pulmatrix Announces Third Quarter 2024 Financial Results and Provides Corporate Update - PRNewsWire
- 4 months ago - Pulmatrix Announces Second Quarter 2024 Financial Results and Provides Corporate Update - PRNewsWire
- 7 months ago - Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation - PRNewsWire
- 8 months ago - Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100) - PRNewsWire
- 8 months ago - Pulmatrix Announces First Quarter 2024 Financial Results and Provides Corporate Update - PRNewsWire